<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364089</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2012/34</org_study_id>
    <nct_id>NCT02364089</nct_id>
  </id_info>
  <brief_title>Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas</brief_title>
  <acronym>CHIRACIC</acronym>
  <official_title>Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective is to evaluate the consequences of surgical removal of SCSI on
      hypertension and cardiovascular risk factors in order to determine on an evidence-based basis
      if surgical excision of SCSI is preferable to an intensive medical regimen in patients with
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenal incidentalomas are unsuspected adrenal masses found during abdominal imaging. With
      the widespread use of computed tomography and MRI, adrenal incidentalomas are found in
      approximately 2% of patients. In an endocrinology setting, the majority of these masses are
      benign adenomas of the adrenal cortex. Approximately 10% of these adenomas display little
      excess of cortisol secretion associated to some degree of secretory autonomy but that are
      insufficient to generate overt Cushing's syndrome (&quot;Subclinical Secreting Cortisol
      incidentalomas&quot; or SCSI). However, hypertension and to a lesser degree obesity and impaired
      glucose tolerance are very frequent amongst patients with SCSI. The hypothesis that the mild
      hypercortisolism associated with SCSI is responsible for these clinical consequences is
      substantiated by few studies describing improvement after resection of SCSI. However, these
      studies were retrospective, uncontrolled and suffered from imprecision and numerous
      methodological bias. Thus, whether surgery is more beneficial than medical treatment is
      currently unknown and there is no consensus on the appropriate treatment for SCSI.

      Patient selection Run-In period. Discontinuation of previous antihypertensive treatments and
      prescription of a standardized anti-hypertensive drug regimen (SAHR). Monthly Blood Pressure
      (BP) measurement using home BP monitoring. The duration of the Run-In periods will be ≤ 6
      months and will end when BP will be controlled with the SAHR at two consecutive visits.

      End of RI Second endocrine assessment for eligibility Randomization (Ra): 24h Ambulatory BP
      measurement, anthropometric and metabolic evaluation. Quality of life and cognition
      questionnaires. Randomization in 2 groups : Gr 1 Treatment group : Surgery followed by
      intensive medical care ; Gr 2 : Control Group : intensive medical care only.

      Ra + 1Mo: Surgery in Group 1 Ra + 2.5 Mo to Ra + 13 Mo: 6 weeks interval follow-up Evaluation
      of home BP monitoring and adaptation of the SAHR. A step by step reduction of the SAHR will
      be attempted in the two patient groups at Ra+2.5Mo. A second attempt will systematically be
      performed in both groups at Ra+8.5 Medical evaluation of associated metabolic conditions
      (obesity, diabetes, dyslipidemia) and adaptation of treatments Record of medical events and
      side effects of treatments Ra + 13Mo: Final evaluation. Endocrine assessment. 24h Ambulatory
      BP measurement, anthropometric and metabolic evaluation. Quality of life and cognition
      questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure value and SAHR step 12 months after inclusion</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment response will defined as a reduction of at least 1 step of SAHR at the end of the study, with BP maintained within the study objectives (125-135 mm Hg systolic and 75-85 mm Hg diastolic) according to self-measurement at home.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive treatment score and daily drug dose</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications in the two strategies.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct costs of the two strategies.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of predictive factors for the success of surgery on BP</measure>
    <time_frame>12 months</time_frame>
    <description>age, family history of hypertension, duration of hypertension, kidney function, biochemical endocrine abnormalities, urinary steroid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients requiring antihypertensive treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hours ambulatory blood pressure monitoring values</measure>
    <time_frame>At inclusion (day 0) and at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose and lipid lowering agents values</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors/markers level</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of the two therapeutic strategies with regard to cardiovascular risk factors/markers: BMI, body composition evaluated by DEXA, abdominal fat evaluated on CT-scan, fasting blood glucose and insulin, HbA1C, HOMA-IR (homeostasis model of assessment of insulin resistance) and OGTT (oral glucose tolerance test), blood lipids, pro-inflammatory adipokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with persistent diabetes, dyslipidemia and metabolic syndrome</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>At inclusion and 12 months</time_frame>
    <description>Comparison of the two therapeutic strategies with regard to quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Adrenal Incidentalomas</condition>
  <arm_group>
    <arm_group_label>Surgery followed by intensive medical care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic surgical removal of the adrenal tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive medical treatment only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standardized medical treatment of hypertension by SAHR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic surgical removal of the adrenal tumor</intervention_name>
    <arm_group_label>Surgery followed by intensive medical care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standardized medical treatment of hypertension by SAHR</intervention_name>
    <description>Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:
step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )
step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)
step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg
step 4: Add-on of Indapamide LP 1.5 mg
step 5: Add-on of Spironolactone 25 mg
step 6: Add-on of Bisoprolol 10 mg
step 7: Add-on of Prazosine LP 5mg/day.</description>
    <arm_group_label>Intensive medical treatment only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≤ 80 years.

          -  Incidentally discovered unilateral SCSI:

               -  Adrenocortical tumor on CT (spontaneous density &lt; 20 HU and/or relative wash-out
                  &gt; 40%, absolute wash-out &gt; 60% ) and &gt; 2 cm in size.

               -  Impaired DST (cortisol &gt; 138 nmol/L or 5 µg/dL)

        OR

        • Impaired DST (cortisol &gt; 50 83 nmol/L or 1,8 3 µg/dL) AND one biological abnormality of
        the corticotropic axis at study entry:

          -  8 a.m. plasma ACTH &lt; 2.2 pmol/L (10 pg/ml),

          -  In case of ACTH at 8 a.m. between 10 and 20 pg/mL (2.2 and 4.4 pmol/L), peak of ACTH &lt;
             30 pg/mL (6.6 pmol/L) after a CRH test

          -  midnight cortisol &gt; 150 nmol/L (5.4 µg/dL)

          -  elevated late-evening salivary cortisol according to the range of the assay

          -  increased 24-hour free urinary cortisol but &lt;2.0-fold the laboratory upper normal
             limit.

          -  Systolic or diastolic hypertension treated

        OR

          -  Systolic or diastolic hypertension (&gt; 135/85 mmHg) not treated assessed on standard
             blood pressure self-measurement device.

          -  Written informed consent signed by patient and investigator

        Exclusion Criteria:

          -  Age &gt; 80 years.

          -  Bilateral incidentaloma.

          -  Incidentally adrenocortical tumor &lt; 2 cm

          -  History of myocardial infarction, pulmonary edema or stroke during the previous year

          -  Malignant hypertension (&gt; 175-115 mm Hg on self-measurement)

          -  Beta-blocker treatment that cannot be suspended.

          -  Free urinary cortisol &gt; 2.0-fold upper normal limit

          -  08h00 plasma ACTH concentration &gt; 4.4 pmol/L (20 pg/ml)

          -  Chronic renal insufficiency (clearance &lt; 30 mL/min)

          -  Exogenous corticosteroid treatment by general or local route (inhaled, eye or ear
             drops , ophthalmic ointment, topical skin application, ear infiltration) during the 6
             months before the trial

        OR

        • Need for Corticosteroid treatment

        OR

        • Medication interfering with dexamethasone metabolism.(54)

          -  Pregnancy

          -  Life-threatening pathology (in the short term)

          -  Contra-indications to surgery

          -  Lack of control of blood pressure at the end of the Run-In period

          -  Dissipation of the biological endocrine criteria for SCSI at the end of the Run-In
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul PEREZ, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine TABARIN, Professor</last_name>
    <phone>+33 5 57 65 64 33</phone>
    <email>antoine.tabarin@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah CAZENAVE</last_name>
    <phone>+33 5 57 65 62 77</phone>
    <email>sarah.cazenave@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Médecine Interne, Endocrinologie et Nutrition - CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard GOICHOT, Professor</last_name>
      <phone>+33 3 88 12 75 93</phone>
      <email>Bernard.Goichot@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Endocrinologie, Diabétologie, maladies métaboliques - CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <state>Aquitaine</state>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine TABARIN, Professor</last_name>
      <phone>+33 5 57 65 64 33</phone>
      <email>antoine.tabarin@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sarah CAZENAVE</last_name>
      <phone>+33 5 57 65 62 77</phone>
      <email>sarah.cazenave@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie - Niveau 18 - Caen CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <state>Basse-Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves REZNIK, Professor</last_name>
      <phone>+33 2 31 06 45 86</phone>
      <email>reznik-y@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie -Diabète-Nutrition - CHU de REIMS</name>
      <address>
        <city>Reims</city>
        <state>Champagne-Ardenne</state>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte DELEMER, Doctor</last_name>
      <phone>+33 3 26 78 81 01</phone>
      <email>bdelemer@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Diabétologie, Nutrition - CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <state>Haut De France</state>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel DESAILLOUD, Pr</last_name>
      <phone>03.22.45.58.97</phone>
      <phone_ext>+33</phone_ext>
      <email>Desailloud.Rachel@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinologie, Diabète et Maladies Métaboliques - CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Haute-Normandie</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé LEFEBVRE, Professor</last_name>
      <phone>+33 2 32 88 90 81</phone>
      <email>Herve.Lefebvre@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie et des Maladies de la Reproduction- Assistance Publique - Hôpitaux de Paris - Hôpial Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <state>ILE DE France</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques YOUNG</last_name>
      <email>jacques.young@bct.ap-hop-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris - Hôpital COCHIN</name>
      <address>
        <city>Paris</city>
        <state>ILE DE France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme BERTHERAT, Professor</last_name>
      <phone>+33 1 58 41 18 95</phone>
      <email>jerome.bertherat@ch.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie et Gynécologie - Assistance Publique - Hôpitaux de Paris - Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>ILE DE France</state>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Service d'Hypertension et de Médecine Vasculaire - Assistance Publique - Hôpitaux de Paris - Hôpital européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>ILE DE France</state>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-François PLOUIN, Professor</last_name>
      <phone>+33 1 56 09 37 71</phone>
      <email>pierre-francois.plouin@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie - Saint-Antoine - AP-HP</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie CHRISTIN-MAITRE, Pr</last_name>
      <phone>01.49.28.24.10</phone>
      <phone_ext>+33</phone_ext>
      <email>sophie.christin-maitre@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie - CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <state>Lorraine</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie et Maladies Métabolique - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CARON, Professor</last_name>
      <phone>+33 5 67 77 17 01</phone>
      <email>caron.p@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Diabétologie et Métabolisme - CHRU de LILLE</name>
      <address>
        <city>Lille</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine VANTYGHEM, Professor</last_name>
      <phone>+33 3 20 44 45 35</phone>
      <email>mc-vantyghem@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département Endocrinologie-Diabétologie -Nutrition - CHU d'ANGERS</name>
      <address>
        <city>Angers</city>
        <state>Pays De La Loire</state>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine LABOUREAU-SOARES, Doctor</last_name>
      <phone>+33 2 41 35 45 93</phone>
      <email>sasoares@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIC Endocrinologie-Nutrition - CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand CARIOU, Professor</last_name>
      <phone>+33 2 53 48 27 07</phone>
      <email>bertrand.cariou@univ-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Diabète et Maladies Métaboliques - Assistance publique - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Côte d'Azur</state>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry BRUE, Professor</last_name>
      <phone>+33 4 91 38 65 97</phone>
      <email>Thierry.BRUE@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Endocrinologie - CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <state>Rhône-Alpes</state>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Endokrinologie, Diabetes und Ernährungsmedizin, Campus Mitte, Medizinische Klinik - Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tina Kienitz</last_name>
      <email>tina.kienitz@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik IV, Endocrine Research Unit - Ludwig-Maximilians-Universität</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Beuschlein</last_name>
      <email>Felix.Beuschlein@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine I, Endocrine and Diabetes Uni -University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin FAßNACHT, Pr</last_name>
      <email>Fassnacht_M@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica di Endocrinologia e Malattie del Metabolismo, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgio Arnaldi</last_name>
      <email>Giorgio.Arnaldi@ospedaliriuniti.marche.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>S Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uberto Pagotto</last_name>
      <email>uberto.pagotto@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University-Hospital of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Scaroni</last_name>
      <email>carla.scaroni@unipd.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Casa Sollievo della Sofferenza&quot; Hospital</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfredo Scillitani</last_name>
      <email>endocrino@operapadrepio.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Terzolo</last_name>
      <email>massimo.terzolo@unito.it</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenal Incidentaloma</keyword>
  <keyword>Subclinical Cushing's syndrome</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cardiovascular Risk Factors</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Surgery of adrenal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocortical Adenoma</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

